WisdomTree International Price, Forecast, Insider, Ratings, Fundamentals & Signals

Aubagne, france--(business wire)--regulatory news: sartorius stedim biotech (ssb) (paris:dim), a leading partner of the biopharma industry, has continued on its growth track, and reported a double-digit increase in sales revenue, order intake and earnings for the first nine months of 2019. “after a stronger-than-expected first half, growth momentum remained high in the third quarter. we have been benefiting from ongoing high demand across all regions and product categories and, beyond this, have continued to grow faster than the market,” said dr. joachim kreuzburg, chairman of the board and ceo. “against the backdrop of continued healthy end-market dynamics, we now expect that the upper end of our sales growth forecast of about 12% to 16% will be reached...

Aubagne, france--(business wire)--regulatory news: with double-digit increases in sales revenue and earnings, sartorius stedim biotech (ssb) (paris:dim), a leading partner of the biopharma industry, continues on the growth track. “momentum developed very strongly in the course of this year, even if we adjust for relative moderate comparables particularly in the third quarter of 2017. we grew dynamically across all product categories and geographies and increased our profitability significantly. conditions in the biopharma market continue to be healthy and demand for our products remains high. backed by a strong order intake, we see us well on track to deliver on our ambitious 2018 targets,” said dr...

Aubagne, france--(business wire)--regulatory news: sartorius stedim biotech (ssb)(paris:dim), a leading partner of the biopharma industry, has continued on the growth track, delivering double-digit increases in sales revenue and earnings in the first half of 2018. “especially the second quarter came in somewhat ahead of our initial expectations,” said joachim kreuzburg, chairman of the board and chief executive officer. “this dynamic performance was broad-based, with both single-use products and equipment contributing to growth. in view of our strong order intake, we expect that this momentum will continue on into the second half, and therefore raise our forecast for the full year.” business development of the group in the first half of 2018, sales revenue rose by 11...

Aubagne, france--(business wire)--regulatory news: sartorius stedim biotech (ssb)(paris:dim), a leading partner of the biopharma industry, successfully started off the year 2018. “in the first quarter, we have seen continued positive business momentum in all regions. on the currency side, we faced considerable headwinds due to the depreciation of the u.s. dollar against the euro, which also affected our profitability. order intake developed positively, giving us confidence that we are well on track to deliver on our full-year targets,” said ceo dr. joachim kreuzburg. business development of the group in the first three months of 2018, sartorius stedim biotech increased its sales revenue in constant currencies by 9...

Aubagne, france--(business wire)--regulatory news: unaudited figures 1 according to customers’ location 2 underlying ebitda = earnings before interest, taxes, depreciation and amortization, adjusted for extraordinary items 3 underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items and non-cash amortization, as well as based on a normalized financial result and tax rate solid revenue growth despite a high prior-year base; order intake gaining momentum given the high revenue base after two extraordinarily strong years and a partially challenging business environment, sartorius stedim biotech (ssb), a leading supplier for the biopharmaceutical industry, showed robust development in fiscal 2017 with an increase in sales revenue by around 4...

A Deeper Look At Our International Dividend Index Rebalance

We expect a global recession that affects small businesses and consumers most directly. We estimate Q2 U.S. GDP down 13% or more, q-o-q annualized; 2020 U.S. GD

Whether you're an expeienced investor or new to the game, these 10 mid-cap ETFs are great additions to your portfolio for the next decade.

The energy sector posts a 3.38% gain in Q4 and was 15.11% higher in 2019. Double-digit percentage gains in WTI and Brent crude oil in Q4. Products underperform